Myc, Aurora Kinase A, and mutant p53 R172H co-operate in a mouse model of metastatic skin carcinoma

Oncogene

Volumn 31, Issue 21, 2012, Pages 2680-2690

  Torchia, E C ^a   Caulin, C ^b   Acin, S ^b   Terzian, T ^a   Kubick, B J ^a   Box, N F ^a   Roop, D R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aurora Kinase A; genomic instability; Myc; p53; SCC; tumor progression

Indexed keywords

AURORA A KINASE; DNA; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER STAGING; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; GAIN OF FUNCTION MUTATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; INTEGRIN GENE; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; RHO GENE; SKIN CARCINOMA; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENES, MYC; GENOMIC INSTABILITY; INTEGRINS; MICE; MUTATION; PAPILLOMA; PROTEIN-SERINE-THREONINE KINASES; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84861531111     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.441     Document Type: Article

References (71)

1. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. (2006). The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 55: 490-500. (Pubitemid 44209289)
2. Birkenfeld J, Nalbant P, Bohl BP, Pertz O, Hahn KM, Bokoch GM. (2007). GEF-H1 modulates localized RhoA activation during cytokinesis under the control of mitotic kinases. Dev Cell 12: 699-712. (Pubitemid 46671149)
3. Birkenfeld J, Nalbant P, Yoon SH, Bokoch GM. (2008). Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell Biol 18: 210-219.
4. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W et al. (2009). Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer 66: 372-378.
5. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J et al. (2008). Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45: 535-538.
6. Boukamp P. (2005). Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 26: 1657-1667. (Pubitemid 41487981)
7. Brosh R, Rotter V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
8. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048. (Pubitemid 44325930)
9. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW et al. (2007). An inducible mouse model for skin cancer reveals distinct roles for gain-and loss-of-function p53 p53 mutations. J Clin Invest 117: 1893-1901. (Pubitemid 47036323)
10. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY et al. (2010). Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 12: 457-467.
11. Cheok CF, Kua N, Kaldis P, Lane DP. (2010). Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 17: 1486-1500.
12. Cheok CF, Verma CS, Baselga J, Lane DP. (2011). Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
13. Cho KB, Cho MK, Lee WY, Kang KW. (2010). Overexpression of cmyc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett 293: 230-239.
14. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. (2003). NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643. (Pubitemid 36227672)
15. Daya-Grosjean L, Sarasin A. (2005). The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res 571: 43-56. (Pubitemid 40313431)
16. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A et al. (2010). Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116: 1498-1505.
17. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
18. Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A et al. (2009). The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des 15: 1373-1384.
19. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. (2010). p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 222: 129-137.
20. Euvrard S, Kanitakis J, Claudy A. (2003). Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691. (Pubitemid 36459475)
21. Fukasawa K. (2005). Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19. (Pubitemid 41506955)
22. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
23. Harris SL, Levine AJ. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908. (Pubitemid 40638098)
24. Haughey BH, von Hoff DD, Windle BE, Wahl GM, Mock PM. (1992). c-myc oncogene copy number in squamous carcinoma of the head and neck. Am J Otolaryngol 13: 168-171.
25. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. (Pubitemid 40719130)
26. Hochberg Y, Benjamini Y. (1990). More powerful procedures for multiple significance testing. Stat Med 9: 811-818. (Pubitemid 20343989)
27. Huang da W, Sherman BT, Lempicki RA. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
28. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T et al. (2003). Expression profiling of epithelial plasticity in tumor progression. Oncogene 22: 7155-7169. (Pubitemid 37378548)
29. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
30. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. (2009). Rho GTPase function in tumorigenesis. Biochim Biophys Acta 1796: 91-98.
31. Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK. (2010). Biology of Aurora A kinase: Implications in cancer manifestation and therapy. Med Res Rev 31: 757-793.
32. Kemp CJ, Donehower LA, Bradley A, Balmain A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74: 813-822. (Pubitemid 23270601)
33. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R et al. (2006). Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25: 130-138. (Pubitemid 43050011)
34. Kozma L, Kiss I, Szakall S, Ember I. (1994). Investigation of c-myc oncogene amplification in colorectal cancer. Cancer Lett 81: 165-169. (Pubitemid 24184651)
35. Kreimer-Erlacher H, Seidl H, Back B, Cerroni L, Kerl H, Wolf P. (2003). High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plusultraviolet-A-treated psoriasis patients. J Invest Dermatol 120: 676-682. (Pubitemid 36344013)
36. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. (Pubitemid 40017691)
37. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK et al. (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311. (Pubitemid 39577940)
38. Lim SK, Gopalan G. (2007). Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J 403: 119-127. (Pubitemid 46569873)
39. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK et al. (2000). High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97: 4174-4179. (Pubitemid 30226106)
40. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D et al. (2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 20: 1331-1342. (Pubitemid 43727593)
41. Mizuarai S, Yamanaka K, Kotani H. (2006). Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 66: 6319-6326.
42. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. (Pubitemid 36792858)
43. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
44. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860. (Pubitemid 40017690)
45. Ozakyol A, Ozdemir M, Artan S. (2006). Fish detected p53 deletion and N-MYC amplification in colorectal cancer. Hepatogastroenterology 53: 192-195.
46. Paterson IC, Eveson JW, Prime SS. (1996). Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol 32B: 150-153.
47. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. (1991). Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 4: 196-202.
48. Prochownik EV, Li Y. (2007). The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 6: 1024-1029. (Pubitemid 46708573)
49. Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D et al. (2002). Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol 21: 297-307. (Pubitemid 34497020)
50. Rao CV, Yamada HY, Yao Y, Dai W. (2009). Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis 30: 1469-1474.
51. Rounbehler RJ, Schneider-Broussard R, Conti CJ, Johnson DG. (2001). Myc lacks E2F10s ability to suppress skin carcinogenesis. Oncogene 20: 5341-5349. (Pubitemid 32844065)
52. Saha MN, Micallef J, Qiu L, Chang H. (2010). Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol 63: 204-209.
53. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C et al. (2007). A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67: 10148-10158. (Pubitemid 350070786)
54. Sauer L, Gitenay D, Vo C, Baron VT. (2010). Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 29: 2628-2637.
55. Shen H, Maki CG. (2011). Pharmacologic activation of p53 by smallmolecule MDM2 antagonists. Curr Pharm Des 17: 560-568.
56. Shi J, Stover JS, Whitby LR, Vogt PK, Boger DL. (2009). Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett 19: 6038-6041.
57. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. (1995). Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 131: 796-800.
58. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
59. Sun Y, Nakamura K, Wendel E, Colburn N. (1993). Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827-2831. (Pubitemid 23113510)
60. Sur S, Pagliarini R, Bunz F, Rago C, Diaz Jr LA, Kinzler KW et al. (2009). A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964-3969.
61. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. (2008). The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344. (Pubitemid 351717524)
62. Torchia EC, Chen Y, Sheng H, Katayama H, Fitzpatrick J, Brinkley WR et al. (2009). A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors. Cancer Res 69: 7207-7215.
63. Van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G et al. (2011). The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today 16: 219-228.
64. Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR et al. (1998). Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog 23: 185-192. (Pubitemid 28535822)
65. Wolf P, Kreimer-Erlacher H, Seidl H, Back B, Soyer HP, Kerl H. (2004). The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients. J Invest Dermatol 122: 190-200. (Pubitemid 38114656)
66. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP et al. (2008). Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6: 760-769.
67. Yakut T, Egeli U, Gebitekin C. (2003). Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique. Lung 181: 245-258. (Pubitemid 37323732)
68. Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y et al. (2010). Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Exp Mol Med 42: 759-767.
69. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ et al. (2005). Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406.
70. Zhang B, Schmoyer D, Kirov S, Snoddy J. (2004). GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 5: 16.
71. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. (2007). A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26: 6896-6904. (Pubitemid 47609074)